Warner Biddle is Chief Executive Officer of Kyverna Therapeutics, Inc. (KYTX). The company reported total compensation of $1,814,980 for fiscal year 2025.
| Salary | $625,000 |
|---|---|
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $543,804 |
| Non-equity incentive plan | $468,750 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $177,426 |
| Total | $1,814,980 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Kyverna Therapeutics, Inc. filed April 13, 2026, accession 0001193125-26-152835.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | Chief Executive Officer | $625,000 | $0 | $0 | $543,804 | $468,750 | $0 | $177,426 | $1,814,980 |
| FY2024 | Chief Executive Officer | $182,292 | $650,000 | $0 | $13,760,605 | $375,000 | $0 | $25,000 | $14,992,897 |
Totals as disclosed in each year's own compensation disclosure for Kyverna Therapeutics, Inc..
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Naji Gehchan | Chief Medical and Development Officer | $2,085,173 |
| Warner Biddle this page | Chief Executive Officer | $1,814,980 |
| Marc Grasso | Chief Financial Officer | $1,663,536 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Kyverna Therapeutics, Inc. compensation brief.
Warner Biddle's compensation sits inside Kyverna Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.